text: Yo, check it out, let me break it down for ya,
  Classical Hodgkin lymphoma, it's curable, no doubt,
  But when it relapses, the outcome's been disappointing,
  Patients stuck in a cycle, it's truly disheartening.
  
  After the first failure, options come into play,
  Multiple therapies, tryna find a way,
  Most patients respond, they see some success,
  But a portion keeps relapsing, no time to rest.
  
  The prognosis for rrcHL, it used to be bleak,
  But hold up, there's something new, let me speak,
  Immune checkpoint inhibitors, they entered the scene,
  Anti-PD-1 receptor antibodies, if you know what I mean.
  
  Nivolumab and pembrolizumab, the approved ones,
  For relapsed and refractory cHL, they get it done,
  In Checkmate 205, nivolumab showed its might,
  Objective response rate at 69%, it's a sight.
  
  Pembrolizumab, too, made its mark in the game,
  KEYNOTE-087 study, it ain't the same,
  Overall response rate, 69%, that's high,
  And complete remission rate, 22.4%, oh my!
  
  So there you have it, a breakthrough in sight,
  With immune checkpoint inhibitors, shining bright,
  They're changing the game for rrcHL patients,
  Improving outcomes, bringing hope, that's amazing.